News

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

The trial previously met its primary end point of progression-free survival, and the final overall survival analysis was recently presented at the 2024 World Conference on Lung Cancer.

Breast cancer diagnostics, therapeutics, and biomarker-driven therapy will be important focal points during the 22nd Annual School of Breast Oncology conference.

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small cell lung cancer.

The bispecific T-cell engager tarlatamab showed continued efficacy and tolerable safety, according to follow-up from the phase 2 DeLLphi-301 study.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.

As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and population at large to tailor care for the unique needs of children to maximize recovery and truly help patients thrive.

In FRα-positive, platinum-resistant ovarian cancer, mirvetuximab soravtansine showed improvements in progression-free survival, overall response rate, and overall survival.

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.

The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.

Ifinatamab deruxtecan, a novel antibody-drug conjugate, returned promising response rates at both dose levels evaluated among patients with small cell lung cancer.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

The combination of durvalumab, chemotherapy, and bevacizumab, followed by maintenance with olaparib, durvalumab, and bevacizumab, improved progression-free survival in newly diagnosed advanced ovarian cancer.

IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

Response outcomes with liso-cel were consistent regardless of the presence of high-risk disease features in patients with relapsed/refractory chronic lymphocytic leukemia.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.

Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

IBI363 has earned fast track designation from the FDA for the treatment of previously treated unresectable advanced melanoma.

The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell lymphoma.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.

There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most responders experiencing durable responses.

Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.